Stem cell therapy biotech PrimeGen US is taking the less-traveled special purpose acquisition company (SPAC) route to the ...
The SPAC agreement values PrimeGen US at $1.5 billion in equity and gives it capital to advance its pre-clinical ...
About International Stem Cell Corp. International Stem Cell Corp. operates as a research and development company for the therapeutic market. It focuses on advancing potential clinical applications of ...
Short interest in Intl Stem Cell Corp (OOTC:ISCO) decreased during the last reporting period, falling from 280.30M to 275.20M. This put 1.17% of the company's publicly available shares short. Based on ...
Key HighlightsMotixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease and beta-thalassemia enabling accelerated access to gene therapies73% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results